文献速递白血病MDS 与骨髓增殖性肿瘤造血干细胞移植与细胞治疗

维奈克拉联合去甲基化药物治疗原始细胞期骨髓增殖性肿瘤:32例多中心系列研究

Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases.
PubMed 文献 · Am J Hematol · 2021-05-06

该多中心回顾性研究分析了32例原始细胞期骨髓增殖性肿瘤(MPN-BP)患者接受维奈克拉(Ven)联合去甲基化药物(HMA)治疗的结局。主要终点为完全缓解(CR/CRi),结果显示44%的患者达到CR/CRi,且在不合并复杂核型或K/NRAS突变时缓解率更高。部分缓解患者后续接受了异基因造血干细胞移植。

要点

  • Ven+HMA在MPN-BP中CR/CRi率达44%,尤其无复杂核型或RAS突变者。
  • 合并复杂核型或K/NRAS突变者CR/CRi率仅19%,而无这些异常者达88%。
  • 部分CR/CRi患者后续成功桥接异基因造血干细胞移植。

核心结论

  • Ven联合HMA在MPN-BP中产生较高的CR/CRi率,尤其在不伴RAS突变和复杂核型时,可使部分患者获得移植机会。

研究设计与样本

  • 多中心回顾性研究,纳入32例MPN-BP患者,中位年龄69岁,59%为男性。
  • 所有患者接受Ven联合阿扎胞苷(n=12)或地西他滨(n=20),其中23例初治,9例经其他诱导治疗失败。

主要发现

  • 与历史对照(单用HMA,n=26)相比,Ven+HMA的CR/CRi率(44% vs 4%)和中位生存(8 vs 5.5个月)更优,但总生存差异无统计学意义。
  • 6例达到CR/CRi的患者随后接受了异基因造血干细胞移植。

关键数值与推荐

  • CR/CRi定义为完全缓解伴或不伴血细胞计数恢复。
  • 复杂核型和/或突变包括TP53(41%)、IDH1/2(21%)、ASXL1(21%)、N/KRAS(14%)、SRSF2(10%)、EZH2(10%)和U2AF1(7%)。

临床怎么用

  • 对于MPN-BP患者,Ven+HMA可作为诱导治疗方案,尤其适用于无复杂核型或RAS突变者。
  • 治疗反应良好者可考虑桥接异基因造血干细胞移植。

局限性

  • 回顾性研究,样本量较小(32例),部分数据来自历史对照。
  • 未进行随机对照,生存获益需前瞻性研究验证。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Venetoclax (Ven) combined with a hypomethylating agent (HMA) has now emerged as an effective treatment regimen for acute myeloid leukemia, in both de novo and relapsed/refractory setting. The current multicenter study retrospectively examined Ven + HMA treatment outcome among 32 patients (median age 69 years; 59% males) with blast-phase myeloproliferative neoplasm (MPN-BP). Pre-leukemic phenotype included essential thrombocythemia (ET)/post-ET myelofibrosis (34%), polycythemia vera (PV)/post-PV myelofibrosis (38%) and primary myelofibrosis (28%). Twenty-nine study patients were fully annotated cytogenetically and molecularly (NGS): 69% harbored complex karyotype and/or mutations, including TP53 (41%), IDH1/2 (21%), ASXL1 (21%), N/KRAS (14%), SRSF2 (10%), EZH2 (10%) and U2AF1 (7%). All patients received Ven combined with either azacitidine (n = 12) or decitabine (n = 20); either up front (n = 23) or after failing another induction therapy (n = 9). Complete remission with (CR) or without (CRi) count recovery was achieved in 14 (44%) patients and was more likely to occur in the absence of pre-leukemic PV/post-PV myelofibrosis phenotype (p < .01), complex karyotype (p < .01) or K/NRAS (p = .03) mutations; seven of eight patients (88%) without vs four of 21 (19%) with complex karyotype or K/NRAS mutation achieved CR/CRi (p < .01); all 11 informative patients with pre-leukemic PV/post-PV myelofibrosis phenotype displayed complex karyotype (p < .01). In contrast, neither TP53 (p = .45) nor IDH1/2 (p = .63) mutations affected response. Compared to historical controls treated with HMA alone (n = 26), the CR/CRi rate (44% vs 4%) and median survival (8 vs 5.5 months) were more favorable with Ven + HMA, but without significant difference in overall survival. Importantly, six patients with CR/CRi subsequently received allogeneic hematopoietic stem cell transplant (AHSCT). Note, Ven + HMA produces robust CR/CRi rates in MPN-BP, especially in the absence of RAS mutations and complex karyotype, thus enabling AHSCT, in some patients.

来源:Am J Hematol,查看原文。版权归原作者所有。

引用

  1. Gangat N, Guglielmelli P, Szuber N, et al. Venetoclax with azacitidine or decitabine in blast-phase myeloproliferative neoplasm: A multicenter series of 32 consecutive cases. Am J Hematol. 2021. PMID: 33844862. doi:10.1002/ajh.26186

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。